Form 4: Corcept Therapeutics CFO Atabak Mokari Reports Significant Stock Acquisitions and Tax-Related Dispositions

Corcept Therapeutics' Chief Financial Officer, Atabak Mokari, reported the acquisition of 1,550 shares through a purchase plan and restricted stock awards, alongside the disposition of 519 shares for tax withholding purposes, increasing his total beneficial ownership to 14,065 shares.

Summary

• Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc. (CORT), acquired 775 shares of common stock on June 2, 2025, at a price of $71.68 per share, as part of a purchase plan established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan.
• On the same date, Mr. Mokari also acquired 775 shares underlying unvested restricted stock awards under the Purchase Plan, with a stated price of $0.
• On June 3, 2025, 519 shares were disposed of by the Issuer to satisfy tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. The value used for this disposition was the closing price of $71.68 on June 2, 2025.
• Following these reported transactions, Mr. Mokari's direct beneficial ownership of Corcept Therapeutics common stock stands at 14,065 shares.
• This beneficial ownership total includes 400 shares underlying unvested restricted stock awards granted on September 3, 2024, 231 shares from awards granted on December 2, 2024, and 232 shares from awards granted on March 3, 2025.
• All restricted stock awards and Purchase Plan shares are scheduled to vest 100% on the one-year anniversary of their respective grant dates, provided the Reporting Person satisfies certain requirements, including remaining the beneficial owner of the Purchase Plan Shares through their one-year anniversary.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the Chief Financial Officer's net acquisition of shares, indicating confidence in the company's future. The disposition was for tax purposes, which is a standard procedure and not indicative of negative sentiment.

Positives

• Chief Financial Officer Atabak Mokari acquired a total of 1,550 shares (775 purchased and 775 as restricted stock awards) on June 2, 2025, demonstrating continued confidence in the company's prospects.
• The acquisition of shares through a purchase plan and restricted stock awards aligns the CFO's financial interests directly with those of the company's shareholders.

Negatives

• 519 shares were disposed of to cover tax withholding obligations, which, while a standard practice, represents a reduction in the gross number of shares received from vesting.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider transaction by a key executive at Corcept Therapeutics, a pharmaceutical company. Such filings are routine disclosures and do not typically provide broader industry context, but they offer insights into management's direct investment in the company's equity.

Stakeholder Impact

• Shareholders may view the CFO's increased beneficial ownership as a positive signal of management's alignment with shareholder interests and confidence in the company's prospects.

Next Steps

• The 400 shares from the September 3, 2024 grant are expected to vest on September 3, 2025.
• The 231 shares from the December 2, 2024 grant are expected to vest on December 2, 2025.
• The 232 shares from the March 3, 2025 grant are expected to vest on March 3, 2026.
• The 775 Purchase Plan Shares and 775 unvested restricted stock awards granted on June 2, 2025, are expected to vest on June 2, 2026, provided certain requirements are met, including maintaining beneficial ownership for the Purchase Plan shares.

Key Dates

Recommendation

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Trading, Atabak Mokari, Chief Financial Officer, Stock Acquisition, Restricted Stock Units, Tax Withholding, Beneficial Ownership, SEC Filing